Zurich Cantonal Bank’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Zurich Cantonal Bank’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-378	Closed	-$13K	–	2636
2019 Q1	$13K	Hold	378	–	–	﹤0.01%	2494
2018 Q4	$11K	Hold	378	–	–	﹤0.01%	2543
2018 Q3	$23K	Hold	378	–	–	﹤0.01%	2457
2018 Q2	$28K	Sell	378 -305	-45%	-$23.8K	﹤0.01%	2357
2018 Q1	$45K	Sell	683 -954	-58%	-$72K	﹤0.01%	2138
2017 Q4	$138K	Hold	1,637	–	–	﹤0.01%	1410
2017 Q3	$189K	Buy	+1,637	New	+$172K	﹤0.01%	1045
2017 Q2	–	Sell	-1,777	Closed	-$219K	–	2580
2017 Q1	$219K	Sell	1,777 -19	-1%	-$2.49K	﹤0.01%	985
2016 Q4	$245K	Sell	1,796 -8,717	-83%	-$1.55M	﹤0.01%	933
2016 Q3	$2.09M	Buy	10,513 +62	+0.6%	+$10.7K	0.02%	612
2016 Q2	$1.35M	Buy	10,451 +389	+4%	+$43.3K	0.02%	636
2016 Q1	$941K	Buy	10,062 +3,017	+43%	+$328K	0.01%	719
2015 Q4	$1.43M	Buy	7,045 +311	+5%	+$55.6K	0.02%	625
2015 Q3	$978K	Buy	6,734 +5,164	+329%	+$948K	0.01%	703
2015 Q2	$334K	Buy	1,570 +520	+50%	+$127K	﹤0.01%	897
2015 Q1	$243K	Buy	+1,050	New	+$254K	﹤0.01%	905

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Zurich Cantonal Bank's BLCM Position: Q2 2019 in Review

Zurich Cantonal Bank sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 378 shares — an estimated $13K sold.

Zurich Cantonal Bank first reported a position in BLCM in Q1 2015 and held it in 16 quarters. The position peaked at $2.09M in Q3 2016. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Zurich Cantonal Bank reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Zurich Cantonal Bank sold 378 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $13K.
Zurich Cantonal Bank first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 16 quarters.
Zurich Cantonal Bank's Bellicum Pharmaceuticals, Inc. position peaked at $2.09M in Q3 2016.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Zurich Cantonal Bank's 13F filing for Q2 2019, filed 30 Jul 2019.